Arvinas Inc logo

ARVN - Arvinas Inc Share Price

$38.5 -1.8  -4.5%

Last Trade - 01/04/20

Mid Cap
Market Cap £1.27bn
Enterprise Value £1.04bn
Revenue £34.6m
Position in Universe 1722nd / 6307
Unlock ARVN Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ARVN Revenue Unlock ARVN Revenue

Net Income

ARVN Net Income Unlock ARVN Revenue

Normalised EPS

ARVN Normalised EPS Unlock ARVN Revenue

PE Ratio Range

ARVN PE Ratio Range Unlock ARVN Revenue

Dividend Yield Range

ARVN Dividend Yield Range Unlock ARVN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARVN EPS Forecasts Unlock ARVN Revenue
Profile Summary

Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated December 9, 2014
Public Since September 27, 2018
No. of Shareholders: 110
No. of Employees: 133
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 39,076,828
Free Float (0.0%)
Eligible for
ARVN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARVN
Upcoming Events for ARVN
Wednesday 6th May, 2020 Estimate
Q1 2020 Arvinas Inc Earnings Release
Monday 3rd August, 2020 Estimate
Q2 2020 Arvinas Inc Earnings Release
Similar to ARVN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.